Facing the large variety of life-limiting conditions in children

Jessica I Hoell1,2, Hannah Weber3, Jens Warfsmann3,4,5

  • 1Medical Faculty, Department of Pediatric Oncology, Hematology and Clinical Immunology, Center for Child and Adolescent Health, University of Duesseldorf, Duesseldorf, Germany. jessica.hoell@uk-halle.de.

Insights

Pediatric palliative care (PPC) intensity varies across "Together for Short Lives" (TfSL) groups. Understanding TfSL symptom clusters, like neurological and gastrointestinal issues, improves tailored care for children with life-limiting conditions.

Area of Science:

  • Pediatric Palliative Care
  • Symptom Cluster Analysis
  • Life-Limiting Conditions

Background:

  • Life-limiting conditions in children necessitate specialized pediatric palliative care (PPC).
  • The "Together for Short Lives" (TfSL) association categorizes these conditions into four common illness trajectories.
  • Understanding specific needs within these TfSL groups enhances clinical problem anticipation and care tailoring.

Purpose of the Study:

  • To analyze the palliative care needs and symptom profiles of children within the four TfSL groups.
  • To determine if care intensity and symptom clusters differ significantly among TfSL categories.
  • To inform tailored care strategies by identifying distinct symptom patterns in different TfSL groups.

Main Methods:

  • Retrospective single-center cohort study of 198 children, adolescents, and young adults (CAYAs) in PPC.
  • Categorization of patients into TfSL-1, TfSL-2, TfSL-3, and TfSL-4 groups.
  • Analysis of home visit frequency and symptom clusters, including neurological and gastrointestinal symptoms.

Main Results:

  • Significant differences in palliative care intensity (home visits) were observed across TfSL groups (p < 0.01).
  • TfSL-1 represented the largest patient group and required the most intensive care.
  • Distinct symptom clusters were identified in TfSL-1 (fatigue, appetite loss, nausea, somnolence; dyspnea, fear, myoclonus, seizures, spasticity) and TfSL-3/4 (spasticity; other symptoms).

Conclusions:

  • Palliative care intensity significantly varies between the TfSL groups.
  • Neurological and gastrointestinal symptoms are prominent across all TfSL groups.
  • Identified symptom clusters in TfSL-1 and TfSL-3/4 can guide anticipation of clinical challenges and personalized care.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
184
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses...
163
Immunodeficiency Diseases01:25

Immunodeficiency Diseases

Immunodeficiency disorders are conditions in which the immune system's ability to fight infectious disease and cancer is compromised or entirely absent. The immune system comprises a complex network of cells, tissues, and organs that work together to protect the body from potentially harmful invaders. When this system is deficient or not functioning properly, it leaves the body susceptible to infections, diseases, or other complications.
There are three main causes of immunodeficiency...
1.8K
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
227
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
210
Inborn Errors of Metabolism01:20

Inborn Errors of Metabolism

Phenylketonuria (PKU) is a protein metabolism disorder characterized by high blood levels of the amino acid phenylalanine. This results from a mutation in the gene responsible for phenylalanine hydroxylase, an enzyme that converts phenylalanine into tyrosine. When this enzyme is deficient, phenylalanine builds up in the blood, leading to symptoms such as vomiting, rashes, seizures, growth deficiency, and severe mental retardation. An early diagnosis and a diet restricting phenylalanine intake...
673